News
Kamada reports inhaled AAT reduces inflammation in lungs of bronchiectasis patients
NESS ZIONA, Israel—Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today positive proof of concept data from a phase II, proof of concept study with its Inhaled Alpha-1 Antitrypsin (AAT) in bronchiectasis.
The results indicate that Inhaled AAT, via an optimized eFlow platform nebulizer (PARI Pharma GmbH), provides a positive indication as to its ability to decrease the inflammatory process in the lung. Furthermore, as reported previously, the safety profile demonstrated in this study is very good and is comparable to the one seen in previous studies with Kamada’s inhaled AAT.
The Phase 2 trial, conducted at the Rabin Medical Center in Israel, was a placebo controlled, double-blind, randomized trial that enrolled 21 patients with bronchiectasis. Patients were randomized 2:1 to Inhaled AAT or placebo for 12 weeks. This study was designed to investigate safety and tolerability of Inhaled AAT and to explore its impact on lung inflammation.
